As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company

29 Sep 2022
endpts.com
Acquisition
Ever since disappointing late-stage data on its cancer drug tanked Idera Pharmaceuticals’ stock last year (unhelped by an ill-fated collaboration with AbbVie ), execs have been tightening the belt while searching for something — anything — that may dig the company out of its hole. More than a year later, they finally found it. In an acquisition that is reminiscent of a reverse merger, Idera is buying private biotech Aceragen in an all-stock deal. Instead of cancer, Idera will now be focused on rare, orphan pulmonary and rheumatic diseases. Specifically, it’s placing its hopes on ACG-701 in cystic fibrosis and melioidosis, and ACG-801 in Farber disease. Together, the companies say their cash pool will provide runway into Q3 2023, by which time Aceragen expects to have read out key clinical data. “After a thorough evaluation of strategic alternatives, we and our Board of Directors believe this acquisition represents the highest potential value creation opportunity for Idera’s stockholders,” said Vincent Milano, Idera’s CEO, who will now hand his job to Aceragen CEO John Taylor and transition to a board chair role. Idera’s former lead asset, tilsotolimod, is a toll-like receptor 9 agonisttoll-like receptor 9 agonist that initially spurred promising response rates in melanoma but ultimately flunked a Phase III trial. Combinations with drugs from AbbVie and Bristol Myers Squibb didn’t produce good enough data, either, and AbbVie ultimately cut a trial short. While it had originally hoped to out-license the drug, Idera eventually opened up its scope for the strategy alternatives it could consider. The biotech estimates that Aceragen’s lead programs will have a combined annual peak sales potential of $650 million. But it’s still got a lot to prove.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.